Phillip Pang - 01 Dec 2021 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Chief Medical Officer
Signature
/s/ Howard Horn, Attorney-in-Fact
Issuer symbol
VIR
Transactions as of
01 Dec 2021
Net transactions value
-$325,841
Form type
4
Filing time
03 Dec 2021, 16:22:20 UTC
Previous filing
19 Nov 2021
Next filing
17 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Sale $39,729 -950 -0.95% $41.82 99,327 01 Dec 2021 Direct F1, F2
transaction VIR Common Stock Sale $191,615 -4,409 -4.4% $43.46 94,918 01 Dec 2021 Direct F1, F3
transaction VIR Common Stock Sale $90,405 -2,050 -2.2% $44.10 92,868 01 Dec 2021 Direct F1, F4
transaction VIR Common Stock Sale $4,092 -91 -0.1% $44.97 92,777 01 Dec 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.41 to $42.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.83 to $43.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.